I’ve had a chance to look through the FDA briefing material and have arrived at the view that your expletive Graeme6269 is a little bit mild in comparison to what mine would be.
Tachvon_Nova I would recommend you read the FDA review of study 22. I think you will find that the material QRX has previously released on this study has been highly selective.
I would go a little bit further than this ... but the HC fighting fund has probably got more worthwhile cases to support than me.
There is a reason that QRX has gone in to the AdCom meeting with a high level of shorts (around 60%of recent volume) on QRXPY in the US. And come Wednesday this will result in a transfer of wealth from us to some clever operators in the US.
Southoz
QRX Price at posting:
70.0¢ Sentiment: Sell Disclosure: Held
